Immuno-oncology treatment for multiple myeloma gets US approval30 Nov 2015
The U.S. Food and Drug Administration approved Bristol-Myers Squibb’s drug for the treatment of a form of blood cancer.
The approved treatment is Empliciti and it will be used in multiple myeloma patients in combination with Celgene's Revlimid and common anti-inflammatory drug dexamethasone.
Research has shown that combination treatments increase the time that multiple myeloma patients survive without the disease.
According to the FDA, Empliciti is the second immuno-oncology treatment for multiple myeloma to be approved, after Johnson & Johnson's Darzalex.